Phase II Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Biliary cancer; Biliary tract disorders
- Focus Therapeutic Use
- 15 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 15 Jan 2018 Planned initiation date changed from 1 Apr 2017 to 1 Jan 2018.
- 17 Apr 2017 New trial record